We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG Wins EU Nod to Expand da Vinci SP in Gynecologic Procedures
Read MoreHide Full Article
Key Takeaways
Intuitive Surgical won CE mark approval for da Vinci SP in transvaginal gynecologic procedures in Europe.
ISRG said SP procedures jumped 61% year over year, supported by broader adoption and new indications.
Intuitive Surgical placed 38 SP systems in Q2 2026, lifting the global installed base to 445 systems.
Intuitive Surgical (ISRG - Free Report) recently announced that its da Vinci SP surgical system received CE mark approval in Europe for transvaginal gynecologic procedures, expanding the platform's approved applications in the region and marking a new milestone for its single-port technology.
The expanded indication strengthens Intuitive Surgical's growth runway in women's health and broadens the addressable market for da Vinci SP in Europe. The approval also reinforces the company's strategy of driving procedure growth through regulatory expansion, which could support higher system utilization and recurring revenue over time.
Likely Trend of ISRG Stock Following the News
Following the announcement, shares of ISRG traded flat in yesterday’s trading. Year to date, shares of the company have lost 33.4% compared with the industry’s 8.1% decline. However, the S&P 500 has risen 11.1% in the same timeframe.
The expanded CE mark strengthens Intuitive Surgical's strategy of growing the da Vinci SP platform through new indications and geographic expansion. During its second-quarter 2026 earnings call, management highlighted that SP procedures surged 61% year over year, driven by expanded indications, new instrumentation and broader adoption, while emphasizing continued investment in training and international expansion to unlock future growth.
The latest approval builds on that roadmap by opening a new women's health opportunity in Europe, potentially increasing SP procedure volumes, system utilization and recurring revenue from instruments and accessories as adoption broadens over time.
ISRG currently has a market capitalization of $133.52 million.
Image Source: Zacks Investment Research
More on the News
Intuitive Surgical's latest CE mark approval expands the da Vinci SP system's approved use in Europe to include transvaginal gynecologic procedures, making it the first such indication for the platform globally. The authorization broadens the SP system's applications in women's health while extending its natural orifice surgery portfolio beyond transoral and transanal procedures, supporting the company's strategy of expanding the platform through new indications rather than relying solely on new system placements.
The approval could help increase utilization of the existing da Vinci SP installed base across Europe, a key driver of Intuitive Surgical's recurring revenue model through instruments, accessories and service revenue. The company also noted that more than 1,000 peer-reviewed publications support the safety and efficacy of the da Vinci SP platform, reinforcing confidence as it pursues broader adoption across surgical specialties.
da Vinci SP Maintains Strong Growth Momentum
Intuitive Surgical's latest second-quarter 2026 results highlighted continued momentum for the da Vinci SP platform. The company placed 38 SP systems during the quarter, up from 23 a year ago, taking the global installed base to 445 systems. Meanwhile, SP procedures surged 61% year over year, driven by strong adoption in the United States and Korea, alongside encouraging early traction in Europe, Japan and Taiwan.
Management attributed the platform's growth to expanded indications, new instrumentation and software enhancements, including extended-range instruments and workflow improvements that are helping broaden clinical adoption. In the United States, the SP stapler also continued gaining traction, reaching nearly 60% usage in eligible cases during the quarter, while Intuitive Surgical reiterated that product innovation, training and international expansion remain central to scaling the SP ecosystem over the long term.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global surgical robots market size is projected to grow from $17.2 billion in 2026 to $45.6 billion by 2033, at a CAGR of 14.9%.
The industry’s growth is driven by the rising adoption of robotic-assisted minimally invasive procedures, the increasing demand for surgical precision and the growing use of advanced robotic instruments and accessories across hospitals and surgical centers.
Other News
ISRG recently announced the publication of a large systematic review and meta-analysis in the peer-reviewed Annals of Surgery Open, evaluating outcomes from more than 14 million procedures across 13 common benign conditions. The study found that da Vinci robotic-assisted surgery was associated with statistically significant improvements in several perioperative outcomes compared with laparoscopic and open surgery.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
ISRG Wins EU Nod to Expand da Vinci SP in Gynecologic Procedures
Key Takeaways
Intuitive Surgical (ISRG - Free Report) recently announced that its da Vinci SP surgical system received CE mark approval in Europe for transvaginal gynecologic procedures, expanding the platform's approved applications in the region and marking a new milestone for its single-port technology.
The expanded indication strengthens Intuitive Surgical's growth runway in women's health and broadens the addressable market for da Vinci SP in Europe. The approval also reinforces the company's strategy of driving procedure growth through regulatory expansion, which could support higher system utilization and recurring revenue over time.
Likely Trend of ISRG Stock Following the News
Following the announcement, shares of ISRG traded flat in yesterday’s trading. Year to date, shares of the company have lost 33.4% compared with the industry’s 8.1% decline. However, the S&P 500 has risen 11.1% in the same timeframe.
The expanded CE mark strengthens Intuitive Surgical's strategy of growing the da Vinci SP platform through new indications and geographic expansion. During its second-quarter 2026 earnings call, management highlighted that SP procedures surged 61% year over year, driven by expanded indications, new instrumentation and broader adoption, while emphasizing continued investment in training and international expansion to unlock future growth.
The latest approval builds on that roadmap by opening a new women's health opportunity in Europe, potentially increasing SP procedure volumes, system utilization and recurring revenue from instruments and accessories as adoption broadens over time.
ISRG currently has a market capitalization of $133.52 million.
Image Source: Zacks Investment Research
More on the News
Intuitive Surgical's latest CE mark approval expands the da Vinci SP system's approved use in Europe to include transvaginal gynecologic procedures, making it the first such indication for the platform globally. The authorization broadens the SP system's applications in women's health while extending its natural orifice surgery portfolio beyond transoral and transanal procedures, supporting the company's strategy of expanding the platform through new indications rather than relying solely on new system placements.
The approval could help increase utilization of the existing da Vinci SP installed base across Europe, a key driver of Intuitive Surgical's recurring revenue model through instruments, accessories and service revenue. The company also noted that more than 1,000 peer-reviewed publications support the safety and efficacy of the da Vinci SP platform, reinforcing confidence as it pursues broader adoption across surgical specialties.
da Vinci SP Maintains Strong Growth Momentum
Intuitive Surgical's latest second-quarter 2026 results highlighted continued momentum for the da Vinci SP platform. The company placed 38 SP systems during the quarter, up from 23 a year ago, taking the global installed base to 445 systems. Meanwhile, SP procedures surged 61% year over year, driven by strong adoption in the United States and Korea, alongside encouraging early traction in Europe, Japan and Taiwan.
Management attributed the platform's growth to expanded indications, new instrumentation and software enhancements, including extended-range instruments and workflow improvements that are helping broaden clinical adoption. In the United States, the SP stapler also continued gaining traction, reaching nearly 60% usage in eligible cases during the quarter, while Intuitive Surgical reiterated that product innovation, training and international expansion remain central to scaling the SP ecosystem over the long term.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global surgical robots market size is projected to grow from $17.2 billion in 2026 to $45.6 billion by 2033, at a CAGR of 14.9%.
The industry’s growth is driven by the rising adoption of robotic-assisted minimally invasive procedures, the increasing demand for surgical precision and the growing use of advanced robotic instruments and accessories across hospitals and surgical centers.
Other News
ISRG recently announced the publication of a large systematic review and meta-analysis in the peer-reviewed Annals of Surgery Open, evaluating outcomes from more than 14 million procedures across 13 common benign conditions. The study found that da Vinci robotic-assisted surgery was associated with statistically significant improvements in several perioperative outcomes compared with laparoscopic and open surgery.
ISRG’s Zacks Rank & Key Picks
Currently, ISRG has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.